logo
How AI and robot hives are lowering the risk of bee colony collapse in California

How AI and robot hives are lowering the risk of bee colony collapse in California

Lifting up the hood of a Beewise hive feels more like you're getting ready to examine the engine of a car than visit with a few thousand pollinators.
The unit — dubbed a BeeHome — is an industrial upgrade from the standard wooden beehives, all clad in white metal and solar panels. Inside sits a high-tech scanner and robotic arm powered by artificial intelligence. Roughly 300,000 of these units are in use across the U.S., scattered across fields of almond, canola, pistachios and other crops that require pollination to grow.
It's not exactly the romantic vision of a beehive or beekeeper lodged in the cultural consciousness, but then that's not what matters; keeping bees alive does. And Beewise's units do that dramatically better than the standard hive, providing constant insights on colony health and the ability to provide treatment should it start to falter.
The U.S. has observed a startling uptick in the number of die-offs since the mid-2000s as beekeepers have struggled to keep pace with the rise of disease-carrying mites, climate extremes and other stressors that can wipe out colonies. That's endangering billions of dollars in crops from almonds to avocados that rely on the pollinators. This past year saw the worst colony losses on record. Beewise has raised nearly $170 million, including a $50 million Series D earlier this month, and it has a plan to change the industry.
AI and robotics are able to replace '90% of what a beekeeper would do in the field,' said Beewise Chief Executive and co-founder Saar Safra. The question is whether beekeepers are willing to switch out tried and true equipment.
Ultimately, the fate of humans is tied to that of bees. Roughly 75% of crops require pollinators, with nuts and fruits particularly dependent. While other species of bees and insects can play a role, they can't replace honeybees.
'There would essentially be no crop without the bees,' said Zac Ellis, the senior director of agronomy at OFI, a global food and ingredient seller.
The beehive hasn't seen much technological innovation in 170 years. The Langstroth hive, named after the American reverend who patented it in 1852, is a simple wooden box with frames that can house the queen and her worker bees, larvae and honey.
'Langstroth hives are easy to work with, break down, build up, manipulate frames, make splits' and move, said Priya Chakrabarti Basu, a Washington State University bee researcher.
These boxes are the backbone of the agriculture industry and the high-value crops that are heavily reliant on the 2.5 million commercial hives that crisscross the U.S. on semitrailers. Beekeepers with thousands of hives will travel from as far away as Florida to provide pollination services for California's $3.9 billion almond crop in spring before moving on to other states and crops.
'Almonds are one of the largest pollination events in the world,' said Ellis, who uses Beewise's hives on 30% of the acres he manages. 'Typically, a grower needs two hives per acre,' each with up to 40,000 bees.
Pollinating the 10,000 acres of almonds, walnuts and pistachios he oversees requires millions of bees doing the brunt of the pollination work.
The number of hives and demand have created a problem, though: Beekeepers are only able to check on their colonies' health every week or two. But a growing number of threats to bees means entire colonies can be wiped out or weakened past the point of no return in just a few days.
Toxic pesticides, a changing climate and a sharp uptick in the invasive, disease-transmitting varroa mite since the 1980s have contributed to the rise of what's known as colony collapse disorder. The exact role each of these issues plays in wiping out colonies is unclear, but they are also likely interacting with each other to take a toll.
'You are rarely going to find a bee who is only, for example, stressed by a mite or a bee who's stressed by a disease only or a bee who's only stressed by poor nutrition,' Chakrabarti Basu said. 'It is always a combination.'
The impacts, though, are clear. From the 12-month period starting last April, more than 56% of commercial colonies were wiped out, according to the Apiary Inspectors of America. Beekeepers have taken a major economic hit as a result: Between last June and March, colony losses cost beekeepers an estimated $600 million, according to the Honey Bee Health Coalition.
While a new hive design alone isn't enough to save bees, Beewise's robotic hives help cut down on losses by providing a near-constant stream of information on colony health in real time — and give beekeepers the ability to respond to issues. Equipped with a camera and a robotic arm, they're able to regularly snap images of the frames inside the BeeHome, which Safra likened to an MRI. The amount of data they capture is staggering.
Each frame contains up to 6,000 cells where bees can, among other things, gestate larvae or store honey and pollen. A hive contains up to 15 frames and a BeeHome can hold up to 10 hives, providing thousands of data points for Beewise's AI to analyze.
While a trained beekeeper can quickly look at a frame and assess its health, AI can do it even faster, as well as take in information on individual bees in the photos. Should AI spot a warning sign, such as a dearth of new larvae or the presence of mites, beekeepers will get an update on an app that a colony requires attention. The company's technology earned it a BloombergNEF Pioneers award earlier this year.
'There's other technologies that we've tried that can give us some of those metrics as well, but it's really a look in the rearview mirror,' Ellis said. 'What really attracted us to Beewise is their ability to not only understand what's happening in that hive, but to actually act on those different metrics.'
That includes administering medicine and food as well as opening and closing vents to regulate temperature or protect against pesticide spraying. Safra noted that after two hurricanes hit Florida last year, BeeHomes in the state were still operational while many wooden hives were destroyed.
That durability and responsiveness has Ellis convinced on expanding their use. Today, BeeHomes are on 30% of his acres, but he said within three years, they're aiming for 100% coverage. Whether other growers and beekeepers are as keen to make the switch remains to be seen, though, given nearly two centuries of loyalty to the Langstroth design.
The startup wants to more than triple the number of BeeHomes in use, reaching 1 million in three years.
'We're in a race against time,' Safra said. 'We might have the best product on planet Earth in 15 years, but it doesn't matter' if there aren't any bees left.
Ellis likened the hives to a Ritz-Carlton for pollinators. The five-star stay appears to suit bees well: Beewise says its units — which it leases to provide pollination services at what it says are market rates — have seen colony losses of around 8%. That's a major drop compared to the average annual loss rate of more than 40%, according to Apiary Inspectors of America, a group that tracks colony health.
'The asset is the bees, that's the revenue-generating asset,' said Safra, noting that losing more than 40% of those assets makes it hard for businesses to cover labor to maintain hives, trailers to transport them and other fixed costs.
Beewise expects to have $100 million in revenue this year, and Safra said it's a year away from profitability. The company declined to share the valuation for its Series D.
It has competition in the bee-saving technology realm. Some companies like Dalan Animal Health are developing vaccines to protect bees against disease. BeeHero and Beeflow (sensing a pattern?) are among those that provide sensors for monitoring health in hives and fields. Both can help improve outcomes at Langstroth hives, but they still require regular beekeeper maintenance.
Chakrabarti Basu from Washington State and her colleagues are also working on using AI to detect bees entering hives. 'The more data sets we can give, the better it'll be trained,' she said. 'Pattern recognition — it could be monitoring a brood frame, it could be looking at anything for estimating colony health or any aspect of colony health — I think AI will probably get better at it.'
Kahn writes for Bloomberg.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

USA Today

time43 minutes ago

  • USA Today

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.

This New Test Could Diagnose Parkinson's With AI
This New Test Could Diagnose Parkinson's With AI

Newsweek

timean hour ago

  • Newsweek

This New Test Could Diagnose Parkinson's With AI

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.

Veteran fund manager who predicted Nvidia stock rally makes surprising move
Veteran fund manager who predicted Nvidia stock rally makes surprising move

Miami Herald

time3 hours ago

  • Miami Herald

Veteran fund manager who predicted Nvidia stock rally makes surprising move

Nvidia (NVDA) shares climbed for five consecutive days this week, closing at a record high of $157.75 on June 27. The rally has made the AI chipmaker the most valuable company again, with a market cap of about $3.85 trillion, ahead of Microsoft (MSFT) and Apple (AAPL) . About three months ago, some pessimistic investors thought that Nvidia's stock had probably reached a dead end as it fell sharply amid macro uncertainties and trade policies. But the stock has gained 67% since its low in early April. Related: Veteran analyst drops bold new call on Nvidia stock Nvidia was hit hard as the U.S. tightened export restrictions on advanced chips in April. The Trump administration said Nvidia would need an export license to ship the H20 processors to China. The H20 chip was designed under the Biden administration's rules. The chipmaker took a $4.5 billion charge in the April quarter and said it would have made an additional $2.5 billion in revenue without the restriction. Nvidia's CEO, Jensen Huang, has long warned that export controls could hurt U.S. chipmakers and even threaten the country's position as the global leader in technology. "If we want the American technology stack to win around the world, then giving up 50% of the world's AI researchers is not sensible," Huang recently said on CNBC. Several developments have driven Nvidia's rally since its April low. The stock first began to recover after the U.S. and China agreed to temporarily pause the elevated tariffs. Sentiment improved further when the Trump administration scrapped the Biden-era AI diffusion rule, which was another export control on advanced AI chips. In May, shares got another boost from news that Nvidia would supply AI chips to Saudi Arabia's Humain, a rising tech player in the region. Related: Veteran analyst offers eye-popping Nvidia, Microsoft stock prediction On May 28, Nvidia posted strong fiscal first-quarter results. Adjusted earnings came in at 96 cents per share on $44.06 billion in revenue, beating Wall Street's estimates of 93 cents and $43.31 billion. The company guided for $45 billion in revenue for the current quarter, just under analysts' forecast of $45.9 billion. Nvidia said that number would have been roughly $8 billion higher without the ongoing export curbs to China. This week's rally was also helped by signs of easing U.S.-China trade tensions. Secretary of Commerce Howard Lutnick told Bloomberg that a trade deal with China has been finalized and signed. The deals said China would ship rare earth metals to the U.S. in exchange for "countermeasure" removal. But it's still unclear whether semiconductors are part of the deal, and chips remain a major sticking point in trade negotiations. As Nvidia shares climbed, Chris Versace, a Wall Street veteran fund manager who oversees TheStreet Pro's portfolio, just sold part of his stake during the rally. On June 26, Versace trimmed roughly 10% of the portfolio's Nvidia stake at $154.06. The gains were just over 100%. Related: Analyst sends bold message on quantum computing stocks after Nvidia CEO's pivot Versace began his career in equity research and now has more than 30 years of experience. He started buying Nvidia stocks in February 2024. He had predicted Nvidia's rally earlier this year, buying more shares in the dip. More Nvidia: Analysts revamp forecast for Nvidia-backed AI stockNvidia stock could surge after surprising Taiwan Semi newsNvidia CEO sends blunt 7-word message on quantum computing "We remain bullish on the prospects for both companies, especially after Wednesday night's quarterly earnings report and lifted outlook from Micron (MU) ," Versace wrote in a note on TheStreet Pro, adding that he still intended to hold Nvidia shares to "maximize AI and data center build out and AI adoption related returns." Versace said the sale reflected his stance as a "disciplined investor," adding that if Nvidia shares continue to rise and push the stock's weight back to 4.5% of the portfolio, "we'll look to lock in additional gains." As of now, Nvidia makes up 4.19% of the portfolio. Related: Top analyst sends bold message on S&P 500 The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store